Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C20H22N2O5 |
| Molecular Weight | 370.3991 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC2=C(C(=O)NC(=N2)C3=CC(C)=C(OCCO)C(C)=C3)C(OC)=C1
InChI
InChIKey=NETXMUIMUZJUTB-UHFFFAOYSA-N
InChI=1S/C20H22N2O5/c1-11-7-13(8-12(2)18(11)27-6-5-23)19-21-15-9-14(25-3)10-16(26-4)17(15)20(24)22-19/h7-10,23H,5-6H2,1-4H3,(H,21,22,24)
| Molecular Formula | C20H22N2O5 |
| Molecular Weight | 370.3991 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 04:36:35 UTC 2023
by
admin
on
Sat Dec 16 04:36:35 UTC 2023
|
| Record UNII |
8R4A7GDZ1D
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
135564749
Created by
admin on Sat Dec 16 04:36:35 UTC 2023 , Edited by admin on Sat Dec 16 04:36:35 UTC 2023
|
PRIMARY | |||
|
DB12000
Created by
admin on Sat Dec 16 04:36:35 UTC 2023 , Edited by admin on Sat Dec 16 04:36:35 UTC 2023
|
PRIMARY | |||
|
8R4A7GDZ1D
Created by
admin on Sat Dec 16 04:36:35 UTC 2023 , Edited by admin on Sat Dec 16 04:36:35 UTC 2023
|
PRIMARY | |||
|
Apabetalone
Created by
admin on Sat Dec 16 04:36:35 UTC 2023 , Edited by admin on Sat Dec 16 04:36:35 UTC 2023
|
PRIMARY | |||
|
1044870-39-4
Created by
admin on Sat Dec 16 04:36:35 UTC 2023 , Edited by admin on Sat Dec 16 04:36:35 UTC 2023
|
PRIMARY | |||
|
DTXSID90146502
Created by
admin on Sat Dec 16 04:36:35 UTC 2023 , Edited by admin on Sat Dec 16 04:36:35 UTC 2023
|
PRIMARY | |||
|
9884
Created by
admin on Sat Dec 16 04:36:35 UTC 2023 , Edited by admin on Sat Dec 16 04:36:35 UTC 2023
|
PRIMARY | |||
|
C171748
Created by
admin on Sat Dec 16 04:36:35 UTC 2023 , Edited by admin on Sat Dec 16 04:36:35 UTC 2023
|
PRIMARY | |||
|
DE-35
Created by
admin on Sat Dec 16 04:36:35 UTC 2023 , Edited by admin on Sat Dec 16 04:36:35 UTC 2023
|
PRIMARY | |||
|
100000169103
Created by
admin on Sat Dec 16 04:36:35 UTC 2023 , Edited by admin on Sat Dec 16 04:36:35 UTC 2023
|
PRIMARY | |||
|
SUB182763
Created by
admin on Sat Dec 16 04:36:35 UTC 2023 , Edited by admin on Sat Dec 16 04:36:35 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET->ACTIVATOR OF EXPRESSION |
|
||
|
TARGET -> INHIBITOR |
Suppressed gene expression of VI mediators in monocytes and endothelial cells by inhibiting BET-dependent transcription induced by multiple inflammatory stimuli. In CVD patients, apabetalone treatment reduced circulating levels of VI mediators, an outcome conducive with atherosclerotic plaque stabilization and MACE reduction.
IC50
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
